EBS - Emergent BioSolutions Inc Stock Price, Fair Value and News

13.99USD+0.19 (+1.38%)Market Closed

Market Summary

USD13.99+0.19

Market Closed

1.38%

EBS Stock Price

View Fullscreen

EBS RSI Chart

EBS Valuation

Market Cap

733.1M

Price/Earnings (Trailing)

-1.3

Price/Sales (Trailing)

0.62

EV/EBITDA

-3.18

Price/Free Cashflow

-5.55

EBS Price/Sales (Trailing)

EBS Profitability

EBT Margin

-47.11%

Return on Equity

-85.15%

Return on Assets

-31.34%

Free Cashflow Yield

-18.03%

EBS Fundamentals

EBS Revenue

Revenue (TTM)

1.2B

Rev. Growth (Yr)

82.84%

Rev. Growth (Qtr)

8.6%

EBS Earnings

Earnings (TTM)

-565.3M

Earnings Growth (Yr)

104.83%

Earnings Growth (Qtr)

118.18%

Breaking Down EBS Revenue

Last 7 days

24.9%

Last 30 days

113.3%

Last 90 days

628.7%

Trailing 12 Months

102.8%

How does EBS drawdown profile look like?

EBS Financial Health

Current Ratio

1.08

Debt/Equity

0.67

Debt/Cashflow

-0.19

EBS Investor Care

Shares Dilution (1Y)

3.87%

Diluted EPS (TTM)

-10.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.2B	0	0	0
2023	977.0M	1.1B	1.1B	1.0B
2022	1.7B	1.6B	1.5B	1.1B
2021	1.7B	1.7B	1.6B	1.8B
2020	1.1B	1.3B	1.3B	1.6B
2019	855.2M	878.2M	1.0B	1.1B
2018	561.8M	681.2M	705.5M	782.4M
2017	502.7M	512.3M	518.8M	560.9M
2016	540.1M	512.4M	496.9M	488.8M
2015	448.4M	457.1M	477.5M	489.3M
2014	323.5M	351.4M	400.3M	450.1M
2013	274.7M	286.7M	309.2M	312.7M
2012	305.2M	287.4M	295.2M	281.9M
2011	257.9M	283.9M	268.7M	273.4M
2010	0	251.9M	269.0M	286.2M
2009	0	0	0	234.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care. The company offers ACAM2000, a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax, an anthrax vaccine; Ebanga, a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard, an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, the company is developing AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

WEBSITE	emergentbiosolutions.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	2500

Emergent BioSolutions Inc Frequently Asked Questions

What is the ticker symbol for Emergent BioSolutions Inc? What does EBS stand for in stocks?

EBS is the stock ticker symbol of Emergent BioSolutions Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Emergent BioSolutions Inc (EBS)?

As of Fri Jul 26 2024, market cap of Emergent BioSolutions Inc is 733.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EBS stock?

You can check EBS's fair value in chart for subscribers.

Is Emergent BioSolutions Inc a good stock to buy?

The fair value guage provides a quick view whether EBS is over valued or under valued. Whether Emergent BioSolutions Inc is cheap or expensive depends on the assumptions which impact Emergent BioSolutions Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EBS.

What is Emergent BioSolutions Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, EBS's PE ratio (Price to Earnings) is -1.3 and Price to Sales (PS) ratio is 0.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EBS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Emergent BioSolutions Inc's stock?

In the past 10 years, Emergent BioSolutions Inc has provided -0.046 (multiply by 100 for percentage) rate of return.